Antimicrobial Agents and Chemotherapy · 1975 · 309 citations · 8 references
PharmacyNephrologyPharmacologyRenal PharmacokineticsRenal PharmacotherapyTherapeutic Drug MonitoringMonitoring In Renal ImpairmentNephrotoxicity ManagementNephrotoxicity MechanismsPeak Concentration AnalysisRenal Dose AdjustmentRenal Function TestsCreatinine Analysis In Body FluidsCreatinine-based DosingGentamicin TherapyLevelsNephrotoxic Medication MonitoringRenal Toxicity GradingSerum Creatinine AssessmentSerum Creatinine Surveillance
Gentamicin blood levels were monitored in 86 patients. Twenty-one patients had valley levels over 2 mug/ml and 36% of these patients developed abnormal serum creatinine or a further rise in creatinine. No patient had a rise in creatinine without a valley level over 2. The peak levels in patients with valleys over 2 were above 10 mug/ml in only one case, whereas four patients had peaks over 10 mug/ml without nephrotoxicity. The mean peak blood levels in patients with a normal creatinine were dose related. An initial dose of 2.0, 1.5, and 1.3 or less mpk (mg/kg) yielded mean peak blood levels of 5.2, 4.7, and 3.7, respectively. To assure an initial peak blood level over 4 mug/ml a loading dose of 2 mpk was required. A rise in peak and valley levels during therapy appeared dose related, being observed in all patients treated with 4.5 mpk daily but not in those receiving 3.0 mpk daily. A radioenzymatic assay was used to validate the standard agar diffusion assay method. The results from the two assays were statistically identical. Valley blood levels of gentamicin may be useful for predicting accumulation of gentamicin which in turn may be correlated with early renal impairment before potentially toxic serum levels of gentamicin develop.
8
Pharmacology of Gentamicin in Man
Louise J. Riff, George Gee Jackson · The Journal of Infectious Diseases · 1971 · 166 citations
Correlation of Serum Creatinine Concentration and Gentamicin Half-Life
Ralph E. Cutler · JAMA · 1972 · 111 citations